Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Prostate Cancer treatment details. Chemotherapy. Hormone. Thomas Jefferson University, Philadelphia, PA, United States

Survival: 21.5 months
Toxicity Grade: 5
Treatments: Chemotherapy
Country: United States
City/State/Province: Philadelphia, PA
Hospital: Thomas Jefferson University
Journal: Link
Date: 3/2012

This phase III study involved men with previously untreated (other than surgery) metastatic castration-resistant prostate cancer who were divided into two separate treatment groups. Group A consisted of 524 patients with a median age of 68.8 years. Group B had 526 patients with a median age of 69.3 years.

Patients in Group A were treated with the chemotherapy agent docetaxel, the biologic therapy agent bevacizumab, and the hormone prednisone.
Patients in Group B were treated with docetaxel and prednisone only.

There were 20 treatment-related deaths in Group A, the causes of which included heart attack, GI hemorrhage, and infection.
There were 6 deaths in Group B, the causes of which included heart attack and infection.

The median overall survival rates for groups A and B were 22.6 and 21.5 months, respectively.

This study was partially supported by the pharmaceutical company Roche-Genentech.

Correspondence: Dr. William Kevin Kelly; email:

E-mail to a Friend Email Physician More Information